ManuelFromGermany Posted - 2 days ago

$QLGN today is the day 🚀🚀🚀

Komo40 Posted - 2 days ago

$QLGN What positive news? There's nothing positive here, just fraud. The idiots don't even have money to finance the ridiculous pipeline. This company is bankrupt. Maybe if employees sell liver, kidneys, heart you can go to phase 2 or not.

General_Stock Posted - 2 days ago

$QLGN come on… going down on positive news??

Komo40 Posted - 3 days ago

$QLGN This is the new Super Pipeline, what happened to it? where did that damn $120,000,000 go. Put everyone involved in prison immediately. Dirty scammers.

Komo40 Posted - 3 days ago

$QLGN Hey, don't believe a word here. Here everyone is cheated and ashes. This is the old pipeline, look at the upper pipeline, do you see any difference?

Finnisher2M Posted - 3 days ago

$QLGN 👀📈✅

DonCorleone77 Posted - 3 days ago

$QLGN Qualigen Therapeutics, Marizyme enter co-development agreement for DuraGraft Marizyme announced a Co-Development Agreement with Qualigen Therapeutics to advance the commercialization of Marizyme's first-in-class FDA cleared product, DuraGraft. DuraGraft was granted a De Novo - FDA Clearance on October 4, 2023, from the U.S. Food and Drug Administration. DuraGraft is labeled for use as a vascular conduit solution indicated for adult patients undergoing Coronary Artery Bypass Grafting surgeries and is intended for the flushing and storage of the saphenous vein grafts used in CABG surgery. According to the Society of Thoracic Surgeons, there are over 500,000 CABG procedures performed annually in the U.S., representing a major market for this commercial-ready product. Pursuant to the Agreement, Qualigen will help support the commercial launch in the United States of DuraGraft, including post-clearance clinical studies to advance the use of DuraGraft in the U.S., by providing up to $1.5 million in funding over the next several months for these purposes. In return, Qualigen will receive a share of Marizyme's gross profit on future U.S. sales of the product, capped at a 2X return on Qualigen's invested capital. Qualigen has also purchased an exclusive negotiation period ending May 31, 2024, for purposes of proposing and outlining a broader strategic relationship between the two companies

ManuelFromGermany Posted - 3 days ago

$QLGN tonight 🚀

ManuelFromGermany Posted - 4 days ago

$QLGN today is the day 🚀🚀🚀❤️

st_89 Posted - 6 days ago

$QLGN where's that idiot @ManuelFromGermany gone? You've been saying "today 🚀" for ages now you clown, what happened? 🤡🤡🤡

BeginnerSinner Posted - 1 week ago

$QLGN tomorrow is a new high

Superbad787 Posted - 1 week ago

$QLGN tomorrow 🚀

Natelys_Hoe Posted - 1 week ago

$QLGN Qualigen Therapeutics, the poster company that lost $120 million and never made a product.

DonCorleone77 Posted - 1 week ago

$QLGN 2 of 2 - Qualigen Therapeutics announces presentation on Pan-RAS Inhibitors ....driven Malignant Peripheral Nerve Sheath Tumors." Abstract #3320 - "Novel Direct Pan-RAS Inhibitors" - Howard Donninger, Rachel Ferril, Becca von Baby, Joe Burlison, Mike Sabo, Tariq Arshad, Rob Monsen, John Trent, and Geoffrey J. Clark - Results demonstrated the compounds' role as Pan-RAS inhibitors. These compounds effectively target and disrupt the activity and signaling of various RAS mutations, including K-RAS, H-RAS, and N-RAS, impacting both mutant and wild type variants. Encouragingly, in vivo studies indicate minimal toxicity associated with these compounds, likely due to their selective suppression of RAS signaling at the administered doses. These results hint at a promising therapeutic potential for Pan-RAS inhibitors in clinical settings, emphasizing their significance in cancer treatment strategies.

DonCorleone77 Posted - 1 week ago

$QLGN 1 of 2 - Qualigen Therapeutics announces presentation on Pan-RAS Inhibitors Qualigen Therapeutics announces a poster presentation on its preclinical Novel Direct Pan-RAS Inhibitors was presented at the American Association for Cancer Research Annual Meeting 2024 held April 5 - 10 in San Diego, California. "We continue to see cancers developing resistance to current clinical agents that target a particular K-RAS mutation, and we remain optimistic that a more broad-based Pan-RAS inhibitor may help resolve these issues", commented Michael Poirier, Qualigen's Chairman and CEO. "The data show that our Pan-RAS inhibitors can interfere with K-RAS, H-RAS and N-RAS activity and signaling, on both mutant and wild type RAS. This suggests there could be a viable window for Pan-RAS inhibitors in patients with RAS driven tumors, as well as a potentially broader application to cancers not usually associated with RAS, such as certain classes of Ovarian, Breast, and NF1 loss....

Stock_Titan Posted - 1 week ago

$QLGN Qualigen Therapeutics' Novel Direct Pan-RAS Inhibitors Presented at American Association of Cancer Research (AACR) 2024 Annual Meeting https://www.stocktitan.net/news/QLGN/qualigen-therapeutics-novel-direct-pan-ras-inhibitors-presented-at-hzr13f0ybkn4.html

Superbad787 Posted - 1 week ago

$QLGN tomorrow 🚀

dcajic2 Posted - 1 week ago

$QLGN Is it they are trying to spin it that it will be good either other cancers. I just don’t see how this is good. Phase 1 trial looks like it failed

dcajic2 Posted - 1 week ago

$QLGN Third patient is still in the study after 3 months.

dcajic2 Posted - 1 week ago

$QLGN It says that three patients successfully completed cycle 1. Ok. But why did one patient withdraw after 4 months with stable disease and one was withdrawn after 3 weeks. Doesn’t seem great to me

kantorix Posted - 1 week ago

$QLGN How is this not yet bankrupt?

Triptrailz Posted - 1 week ago

$QLGN they’re trying to squeeze the last juice in hopes to keep their paychecks. Don’t get me wrong, I have around 2k shares at a massive loss so I truly hope this goes 99999%+. Even at the slightest margin that the cancer drug was real and effective, our corrupt pharma would never let it succeed. It’s probably all fabricated BS anyways as usual

Marypennsylvanialand Posted - 1 week ago

$QLGN the power of posters, part 9...

DonCorleone77 Posted - 1 week ago

$QLGN Qualigen announces AACR poster featuring early clinical experience with QN-302 Qualigen Therapeutics announces that a poster featuring its early clinical experience with a novel first-in-class G-Quadruplex experimental anti-cancer drug, QN-302, was presented at the American Association for Cancer Research AACR Annual Meeting 2024 held April 5 - 10 in San Diego, California. "These early clinical data from this multi-center Phase 1 study in patients with metastatic pancreatic cancer are encouraging and further corroborate our approach for utilizing QN-302 as a potential treatment for advanced pancreatic cancer," commented Michael Poirier, Qualigen's Chairman and Chief Executive Officer. "The three pancreatic cancer patients in the trial to date had ultimately failed extensive prior therapy including Standard of Care and subsequently received the lowest dose of QN-302, with no Dose Limiting Toxicity or Significant Adverse Events observed..."

TheTradeXchange Posted - 1 week ago

$QLGN - Qualigen Therapeutics Announces Poster Featuring Positive Early Clinical Experience with QN-302, a Novel First-in-Class G-Quadruplex Experimental Anti-Cancer Drug, at the American Association of Cancer Research (AACR) 2024 Annual Meeting

Stock_Titan Posted - 1 week ago

$QLGN Qualigen Therapeutics Announces Poster Featuring Positive Early Clinical Experience with QN-302, a Novel First-in-Class G-Quadruplex Experimental Anti-Cancer Drug, at the American Association of Cancer Research (AACR) 2024 Annual Meeting https://www.stocktitan.net/news/QLGN/qualigen-therapeutics-announces-poster-featuring-positive-early-evjg8zc86mbd.html

ManuelFromGermany Posted - 1 week ago

$QLGN to day🚀

GermanInvest Posted - 1 week ago

$QLGN ch11 coming

Superbad787 Posted - 1 week ago

$QLGN tomorrow 🚀

DuckDagobert Posted - 1 week ago

$QLGN Did you check their pipeline? Everything is deleted. They have only fastpack left! Looks very strange!